Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney

被引:29
作者
Palmer, Biff F. [1 ]
Clegg, Deborah J. [2 ]
Taylor, Simeon I. [3 ]
Weir, Matthew R. [4 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
[2] Cedars Sinai Med Ctr, Biomed Res Dept, Diabet & Obes Res Div, Beverly Hills, CA USA
[3] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD USA
[4] Univ Maryland, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21201 USA
关键词
Diabetic ketoacidosis; Sodium glucose transporter 2 inhibitors; Kidney; Glucose; Transport maximum; KETONE-BODIES; RENAL AMMONIAGENESIS; SGLT2; INHIBITORS; FATTY-ACIDS; SECRETION; CANAGLIFLOZIN; DAPAGLIFLOZIN; STARVATION; OXIDATION; MELLITUS;
D O I
10.1016/j.jdiacomp.2016.05.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic ketoacidosis is a serious metabolic condition that may occur in patients with either Type 1 or Type 2 diabetes. The accumulation of ketoacids in the serum is a consequence of insulin deficiency and glucagon excess. Sodium Glucose Transporter 2 (SGLT2) inhibitors are novel therapeutic treatments for improving glucose homeostasis in patients with diabetes. Through reductions in glucose reabsorption by the kidney, they lower serum glucose in patients with Type 2 diabetes and they improve glucose control whether used alone or in combination with other therapies. Mechanistically, these drugs increase serum ketoacids and increase glucagon production, which in some individuals, can lead to formation of diabetic ketoacidosis. This review will first focus in how the kidney normally handles ketoacids, and second will discuss how the SGLT2 inhibitors affect the kidney in such a way so as to enhance the risk for development of ketoacidosis in susceptible individuals. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1162 / 1166
页数:5
相关论文
共 33 条
[1]   Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].
Bolinder, Jan ;
Ljunggren, Osten ;
Kullberg, Joel ;
Johansson, Lars ;
Wilding, John ;
Langkilde, Anna Maria ;
Sugg, Jennifer ;
Parikh, Shamik .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031
[2]   Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion [J].
Bonner, Caroline ;
Kerr-Conte, Julie ;
Gmyr, Valery ;
Queniat, Gurvan ;
Moerman, Ericka ;
Thevenet, Julien ;
Beaucamps, Cedric ;
Delalleau, Nathalie ;
Popescu, Iuliana ;
Malaisse, Willy J. ;
Sener, Abdullah ;
Deprez, Benoit ;
Abderrahmani, Amar ;
Staels, Bart ;
Pattou, Francois .
NATURE MEDICINE, 2015, 21 (05) :512-U139
[3]  
Comstock J.P., 1990, Clinical Methods: The History, Physical, and Laboratory Examinations, V3rd
[4]   Estrogen regulation of adiposity and fuel partitioning - Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways [J].
D'Eon, TM ;
Souza, SC ;
Aronovitz, M ;
Obin, MS ;
Fried, SK ;
Greenberg, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (43) :35983-35991
[5]   EFFECT OF HYPERKETONEMIA ON RENAL AMMONIA EXCRETION IN MAN [J].
DESIR, G ;
BRATUSCHMARRAIN, P ;
DEFRONZO, RA .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1986, 35 (08) :736-743
[6]   Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program [J].
Erondu, Ngozi ;
Desai, Mehul ;
Ways, Kirk ;
Meininger, Gary .
DIABETES CARE, 2015, 38 (09) :1680-1686
[7]   Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients [J].
Ferrannini, Ele ;
Muscelli, Elza ;
Frascerra, Silvia ;
Baldi, Simona ;
Mari, Andrea ;
Heise, Tim ;
Broedl, Uli C. ;
Woerle, Hans-Juergen .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :499-508
[8]  
FOSTER DW, 1983, NEW ENGL J MED, V309, P159
[9]   Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney [J].
Gopal, E. ;
Umapathy, N. S. ;
Martin, P. M. ;
Ananth, S. ;
Gnana-Prakasam, J. P. ;
Becker, H. ;
Wagner, C. A. ;
Ganapathy, V. ;
Prasad, P. D. .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2007, 1768 (11) :2690-2697
[10]  
GUDER WG, 1992, EUR J CLIN CHEM CLIN, V30, P669